MARKET

XGN

XGN

Exagen Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.31
-0.87
-14.01%
Closed 16:00 08/09 EDT
OPEN
6.50
PREV CLOSE
6.18
HIGH
6.50
LOW
5.09
VOLUME
45.75K
TURNOVER
172.40K
52 WEEK HIGH
14.90
52 WEEK LOW
4.150
MARKET CAP
86.34M
P/E (TTM)
-2.9141
1D
5D
1M
3M
1Y
5Y
RHE, HIHO and FEDU among mid-day movers
Gainers: Cooper-Standard Holdings (CPS) +78%. H...
Seekingalpha · 4d ago
--KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process'
--KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process'
MT Newswires · 5d ago
Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
BRIEF-Exagen Initiates Study To Predict Rheumatoid Arthritis Drug Response (Radr) In Patients With Ra
BRIEF-Exagen Initiates Study To Predict Rheumatoid Arthritis Drug Response (Radr) In Patients With Ra
Reuters · 5d ago
Exagen Initiates Study To Predict Rheumatoid Arthritis Drug Response (RADR) In Patients With RA
 Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic
Benzinga · 5d ago
Exagen GAAP EPS of -$0.78 misses by $0.21, revenue of $8.96M misses by $3.07M
Exagen press release (NASDAQ:<a href="https://seekingalp...
Seekingalpha · 5d ago
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic te...
GlobeNewswire · 5d ago
Exagen Inc. Reports Second Quarter 2022 Results
Records in AVISE® CTD Volume, Ordering Healthcare Providers and AdoptersSAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June ...
GlobeNewswire · 5d ago
More
No Data
Learn about the latest financial forecast of XGN. Analyze the recent business situations of Exagen Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
33.33%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XGN stock price target is 14.50 with a high estimate of 16.00 and a low estimate of 13.00.
High16.00
Average14.50
Low13.00
Current 5.31
EPS
Actual
Estimate
-0.62-0.47-0.31-0.16
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 61
Institutional Holdings: 9.17M
% Owned: 56.39%
Shares Outstanding: 16.26M
TypeInstitutionsShares
Increased
16
526.99K
New
7
167.69K
Decreased
20
111.37K
Sold Out
7
94.83K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-0.36%
Healthcare Providers & Services
+0.27%
Key Executives
Non-Executive Chairman/Independent Director
Brian Birk
President/Chief Executive Officer/Director
Fortunato Rocca
Chief Financial Officer/Secretary
Kamal Adawi
Chief Operating Officer
Mark Hazeltine
Other
Debra Zack
Independent Director
Ana Hooker
Independent Director
Wendy Johnson
Independent Director
Tina Nova
Independent Director
Ebetuel Pallares
Independent Director
Bruce Robertson
Independent Director
Frank Stokes
Independent Director
James Tullis
No Data
No Data
About XGN
Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The Company's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

Webull offers kinds of Exagen Inc stock information, including NASDAQ:XGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XGN stock methods without spending real money on the virtual paper trading platform.